Low levels of serum 25-hydroxyvitamin D (25OHD) show an independent association with asthma, wheeze, bronchitis and chest tightness, reports a recent study which has three levels of adjustment for potential confounders. In addition, higher levels of vitamin D correlate with higher lung function levels.
In children and adolescents with cystic fibrosis (CF), synbiotic supplementation appears to be effective at reducing proinflammatory markers such as interleukin (IL)-6 and -8, and nitric oxide metabolites (NOx), a recent study has found.
Most immune-related toxicities resulting from lung cancer immunotherapy usually involve the skin, lungs, endocrine system and the gastrointestinal (GI) tract and are manageable with immunomodulatory agents such as corticosteroids.
The incidence of grade ≥3 cardiac and respiratory toxicities is higher in decitabine-treated acute myeloid leukaemia (AML) patients with renal dysfunction than in those with normal renal function, a recent study has found. Additionally, this may encourage closer monitoring regardless of baseline cardiac comorbidities.
Higher grip strength is strongly associated with lower all-cause mortality and reduced incidence of and mortality from cardiovascular disease (CVD), respiratory disease, chronic obstructive pulmonary disease (COPD), all cancer and subtypes of cancer, including colorectal, lung and breast cancer, according to a study, adding that such associations are moderately stronger in younger individuals.
A simplified training for cardiopulmonary resuscitation (CPR) for laypersons, which focuses on continuous and with simple hand placement for chest compressions, may improve acquisition and retention of CPR algorithms, as well as the quality of chest compressions than a standard CPR programme, a recent study suggests.
Combining the monoclonal antibody atezolizumab with a carboplatin-paclitaxel chemotherapy regimen and the biologic antiangiogenic agent bevacizumab led to a significant progression-free survival (PFS) benefit in chemotherapy-naïve patients with non-squamous metastatic non-small-cell lung cancer (mNSCLC), according to the IMpower150* trial presented at ELCC 2018.